|

Predictors and Prognostic Factors of Myasthenia Gravis Outcome

RECRUITINGSponsored by Assiut University
Actively Recruiting
SponsorAssiut University
Started2022-01-01
Est. completion2024-12-31
Eligibility
Age16 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05214612

Summary

This study aims to characterize the clinical features, frequency of different subgroups of MG, and identify predictors of treatment responsiveness among different subgroups of MG. The predictors are including primary outcome (percentage of changes in MG scales at baseline at time of enrollment and after 3 months) and secondary outcome (treatment-related adverse events). Also it aims to determine the frequency of patients with refractory MG. This information will be used to understand the trends and mechanisms of disease relapse, and optimal management strategies.

Eligibility

Age: 16 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Age from 16 years and older.
2. Gender: both sexes are included.
3. Clinical Diagnosis of MG with supporting evidence as:

   1. unequivocal clinical response to pyridostigmine
   2. decrement \>10% in repetitive nerve stimulations study (RNS).
4. Willingness to sample collection, imaging study and other disease-related examinations and assessments.

Exclusion Criteria:

1. Age younger than 16 years.
2. History of chronic psychiatric or neurological disorder other than MG that can produce weakness or fatigue.
3. Severe systemic illness affecting life-expectancy.

Conditions13

Autoimmune Diseases of the Nervous SystemCancerMyasthenia GravisMyasthenia Gravis CrisisMyasthenia Gravis with Exacerbation (Disorder)Myasthenia Gravis, Adult FormMyasthenia Gravis, GeneralizedMyasthenia Gravis, Juvenile FormMyasthenia Gravis, OcularNervous System Diseases

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.